In a report released today, David Turkaly from JMP Securities maintained a Buy rating on AxoGen (AXGN – Research Report), with a price target of $20.00. The company’s shares closed last Tuesday at $9.06, close to its 52-week low of $6.87.
According to TipRanks.com, Turkaly is a 3-star analyst with an average return of 2.5% and a 42.4% success rate. Turkaly covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics.
AxoGen has an analyst consensus of Strong Buy, with a price target consensus of $19.00, representing a 125.7% upside. In a report issued on July 12, Nephron also initiated coverage with a Buy rating on the stock with a $21.00 price target.
The company has a one-year high of $20.71 and a one-year low of $6.87. Currently, AxoGen has an average volume of 327.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AxoGen, Inc. engages in the development and market of surgical solutions for peripheral nerves. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. Its products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.
Read More on AXGN:
- JMP Securities Sticks to Their Buy Rating for Neuronetics (STIM)
- Equity Lifestyle (ELS) Receives a Hold from BMO Capital
- Nokia Corporation: Repurchase of own shares on 19.07.2022
- RemSleep Holdings Inc. Issues Correction to July 12th, 2022 Press Release
- TWC Enterprises Limited Increases Ownership Position in Automotive Properties REIT